{"id":10430,"date":"2024-10-30T15:56:43","date_gmt":"2024-10-30T07:56:43","guid":{"rendered":"https:\/\/flcube.com\/?p=10430"},"modified":"2024-10-30T15:56:46","modified_gmt":"2024-10-30T07:56:46","slug":"mindray-reports-q3-2024-financials-international-revenues-surge-over-18-amid-domestic-challenges","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=10430","title":{"rendered":"Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges"},"content":{"rendered":"\n

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760<\/a>) reported its Q3 2024 financial results, revealing revenues of RMB 29.48 billion (USD 4.18 billion) for the first three quarters, reflecting a year-on-year increase of 7.99%. Net profit attributable to the parent company reached RMB 10.64 billion (USD 1.49 billion), up 8.16% from the previous year. The company allocated RMB 2.84 billion (USD 397.97 million) to research and development (R&D), constituting 9.64% of its operational revenues.<\/p>\n\n\n\n

Geographically, Mindray’s international market demonstrated robust growth, surging over 18% in the first three quarters, driven by advancements in high-end strategic customer collaborations and increased adoption of seed businesses such as minimally invasive surgery. Notably, the European and Asia Pacific markets each experienced growth exceeding 30%. In contrast, the domestic market’s growth was muted at less than 2%, attributed to various factors including adjustments in the medical sector and delays in hospital procurement due to budget constraints and non-essential medical demand.<\/p>\n\n\n\n

In terms of production capabilities, Mindray’s in vitro diagnostic (IVD) production line expanded by more than 20% during the first three quarters, spurred by enhanced overseas localization efforts and breakthroughs in larger sample laboratories, with international IVD production growing by over 30%. The company also reported an increase in market share across its chemiluminescence, biochemistry, and coagulation segments, with its chemiluminescence business projected to become the third largest in China. Additionally, the medical imaging production line grew by more than 10%, primarily due to the market reception of its premiere ultra-high-end whole-body ultrasound, the Resona A20, launched late last year.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported its Q3 2024 financial results, revealing…<\/p>\n","protected":false},"author":1,"featured_media":10431,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[27,889],"class_list":["post-10430","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-medical-device","tag-finanical-reports","tag-she-300760"],"yoast_head":"\nMindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported its Q3 2024 financial results, revealing revenues of RMB 29.48 billion (USD 4.18 billion) for the first three quarters, reflecting a year-on-year increase of 7.99%. Net profit attributable to the parent company reached RMB 10.64 billion (USD 1.49 billion), up 8.16% from the previous year. The company allocated RMB 2.84 billion (USD 397.97 million) to research and development (R&D), constituting 9.64% of its operational revenues.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=10430\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=10430\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-30T07:56:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-30T07:56:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/818a4cd6fc0139537ca123f7bd7e865b.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"618\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10430#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10430\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges\",\"datePublished\":\"2024-10-30T07:56:43+00:00\",\"dateModified\":\"2024-10-30T07:56:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10430\"},\"wordCount\":257,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10430#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/818a4cd6fc0139537ca123f7bd7e865b.png\",\"keywords\":[\"Finanical Reports\",\"SHE: 300760\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10430#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10430\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=10430\",\"name\":\"Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10430#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10430#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/818a4cd6fc0139537ca123f7bd7e865b.png\",\"datePublished\":\"2024-10-30T07:56:43+00:00\",\"dateModified\":\"2024-10-30T07:56:46+00:00\",\"description\":\"Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported its Q3 2024 financial results, revealing revenues of RMB 29.48 billion (USD 4.18 billion) for the first three quarters, reflecting a year-on-year increase of 7.99%. Net profit attributable to the parent company reached RMB 10.64 billion (USD 1.49 billion), up 8.16% from the previous year. The company allocated RMB 2.84 billion (USD 397.97 million) to research and development (R&D), constituting 9.64% of its operational revenues.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10430#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10430\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10430#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/818a4cd6fc0139537ca123f7bd7e865b.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/818a4cd6fc0139537ca123f7bd7e865b.png\",\"width\":1024,\"height\":618,\"caption\":\"Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10430#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges - Insight, China's Pharmaceutical Industry","description":"Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported its Q3 2024 financial results, revealing revenues of RMB 29.48 billion (USD 4.18 billion) for the first three quarters, reflecting a year-on-year increase of 7.99%. Net profit attributable to the parent company reached RMB 10.64 billion (USD 1.49 billion), up 8.16% from the previous year. The company allocated RMB 2.84 billion (USD 397.97 million) to research and development (R&D), constituting 9.64% of its operational revenues.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=10430","og_locale":"en_US","og_type":"article","og_title":"Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=10430","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-10-30T07:56:43+00:00","article_modified_time":"2024-10-30T07:56:46+00:00","og_image":[{"width":1024,"height":618,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/818a4cd6fc0139537ca123f7bd7e865b.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=10430#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=10430"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges","datePublished":"2024-10-30T07:56:43+00:00","dateModified":"2024-10-30T07:56:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=10430"},"wordCount":257,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=10430#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/818a4cd6fc0139537ca123f7bd7e865b.png","keywords":["Finanical Reports","SHE: 300760"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=10430#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=10430","url":"https:\/\/flcube.com\/?p=10430","name":"Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=10430#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=10430#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/818a4cd6fc0139537ca123f7bd7e865b.png","datePublished":"2024-10-30T07:56:43+00:00","dateModified":"2024-10-30T07:56:46+00:00","description":"Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported its Q3 2024 financial results, revealing revenues of RMB 29.48 billion (USD 4.18 billion) for the first three quarters, reflecting a year-on-year increase of 7.99%. Net profit attributable to the parent company reached RMB 10.64 billion (USD 1.49 billion), up 8.16% from the previous year. The company allocated RMB 2.84 billion (USD 397.97 million) to research and development (R&D), constituting 9.64% of its operational revenues.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=10430#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=10430"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=10430#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/818a4cd6fc0139537ca123f7bd7e865b.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/818a4cd6fc0139537ca123f7bd7e865b.png","width":1024,"height":618,"caption":"Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=10430#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/818a4cd6fc0139537ca123f7bd7e865b.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10430","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10430"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10430\/revisions"}],"predecessor-version":[{"id":10432,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10430\/revisions\/10432"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/10431"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10430"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10430"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10430"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}